<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nifedipine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nifedipine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nifedipine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10908" href="/d/html/10908.html" rel="external">see "Nifedipine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12643" href="/d/html/12643.html" rel="external">see "Nifedipine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F201399"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adalat CC [DSC];</li>
<li>Procardia XL;</li>
<li>Procardia [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867681"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Adalat XL;</li>
<li>AG-Nifedipine ER;</li>
<li>DOM-NIFEdipine;</li>
<li>JAMP-Nifedipine ER;</li>
<li>M-Nifedipine ER;</li>
<li>MYLAN-NIFEdipine;</li>
<li>PMS-NIFEdipine ER;</li>
<li>PMSC-Nifedipine ER</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F201448"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antianginal Agent;</li>
<li>
                        Antihypertensive;</li>
<li>
                        Calcium Channel Blocker;</li>
<li>
                        Calcium Channel Blocker, Dihydropyridine</li></ul></div>
<div class="block doa drugH1Div" id="F201404"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> The use of IR sublingual nifedipine is <b>not recommended</b> for any indication due to safety concerns.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> When switching from IR (oral administration) to ER formulations, use same total daily dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cdfe901d-a336-46c4-870c-2fa07ecd9f47">Anal fissure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anal fissure (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Administered topically as a local vasodilator in conjunction with supportive measures. Ointment and gel are not commercially available and must be prepared by a licensed compounding facility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bleday.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bleday.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peri-anal:</b> 0.2% to 0.3% ointment or gel: After cleansing, apply around fissure(s) 2 to 4 times daily for 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24035211','lexi-content-ref-Bleday.1','lexi-content-ref-12794583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24035211','lexi-content-ref-Bleday.1','lexi-content-ref-12794583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic stable angina (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, a long-acting dihydropyridine calcium channel blocker (eg, ER nifedipine) may be added; ER nifedipine may also be used as an alternative therapy if there are contraindications or unacceptable adverse effects with beta-blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166210'])">Ref</a></span>). Use of immediate-release nifedipine (oral or sublingual) is not recommended due to increased adverse effects (hypotension and reflex tachycardia), particularly in absence of a beta-blocker.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Extended release: Initial: 30 or 60 mg once daily; increase as needed to effective antianginal dose over 1 to 2 weeks. Doses &gt;90 mg/day are rarely needed; maximum: 120 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Vasospastic angina:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used alone or in combination with nitrates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166210'])">Ref</a></span>). Use of immediate-release nifedipine (oral or sublingual) is not recommended due to increased adverse effects (hypotension and reflex tachycardia).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Extended release: Initial: 30 or 60 mg once daily; increase as needed to effective antianginal dose over 1 to 2 weeks. Doses &gt;90 mg/day are rarely needed; maximum: 120 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c52d7f2-7407-4a35-a79d-768591ea4db6">High-altitude pulmonary edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>High-altitude pulmonary edema (adjunctive therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention</i>: <b>Note:</b> May use as an adjunct to gradual ascent in high-risk individuals (eg, history of high-altitude pulmonary edema) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31248818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Extended release: 30 mg every 12 hours starting 24 hours prior to ascent; continue for 4 to 5 days after reaching maximal altitude; can extend for up to 7 days in individuals who ascend faster than recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.1','lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.1','lexi-content-ref-31248818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i>
<b>Note: </b>Adjunctive to nonpharmacologic measures (eg, oxygen supplementation, portable hyperbaric chamber, gradual descent) or as monotherapy if nonpharmacologic measures are not possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31248818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Extended release: 30 mg every 12 hours; continue until descent is complete, symptoms resolve, and oxygenation is normal for the altitude (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gallagher.1','lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gallagher.1','lexi-content-ref-31248818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use in combination with another appropriate agent (eg, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). IR nifedipine (oral or sublingual) should <b>not</b> be used for acute BP lowering due to risk of hypotension and ischemic complications. However, may consider extended release for severe asymptomatic hypertension (eg, to lower BP over hours) if there is concern that severe BP elevation will precipitate an acute cardiovascular event, such as in patients with known aortic or intracranial aneurysms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Varon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Varon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Extended release: Initial: 30 or 60 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose as needed up to 90 mg once daily; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication adjustment within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9f708dd-ef5e-4e74-8eb4-bbad8f556048">Hypertensive emergency in pregnancy or postpartum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency in pregnancy or postpartum (including acute-onset severe hypertension in preeclampsia/eclampsia) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For acute-onset, severe, persistent hypertension (eg, systolic BP ≥160 mm Hg or diastolic BP ≥110 mm Hg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Extended release: <b>Note:</b> Consider for use in less acute settings when slower BP reduction (eg, within 60 minutes versus 5 to 10 minutes) is sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-August.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-August.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 30 mg; repeat 30 mg after 1 to 2 hours if target BP is not achieved; if systolic or diastolic BP remains above threshold after the second dose, another class of agents should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-August.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-August.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Immediate release (alternative agent): <b>Note:</b> Generally reserved for use when IV access is not available. Some experts avoid use of immediate-release formulations unless immediate BP lowering is warranted (eg, &lt;30 minutes), as it may be associated with precipitous drops in BP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-August.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-August.1'])">Ref</a></span>). Do <b>not</b> puncture capsule or administer sublingually.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 10 mg once; if systolic or diastolic BP remains above target at 20 minutes, give a second dose of 10 or 20 mg orally depending on initial response. Reassess BP again 20 minutes after the second dose; if not at target, give a third dose of 10 or 20 mg depending on previous response. If target BP is not achieved 20 minutes after the third dose, another class of agents should be considered; maximum cumulative dose: 50 mg/treatment episode or 180 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-August.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-August.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3148a3ba-0ac4-46a3-b3b8-7e0b78bd77a6">Pulmonary arterial hypertension, group 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension, group 1 (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only used for group 1 pulmonary arterial hypertension patients with a positive vasoreactivity test and under the care of a pulmonary hypertension specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Extended release: Initial: 30 mg once daily; titrate gradually, with close hemodynamic monitoring; reported dose range: 120 to 240 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-Hopkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-Hopkins.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fed0e48d-298d-453f-bda8-97189c608a2d">Raynaud phenomenon</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Raynaud phenomenon (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Extended release: Initial: 30 mg once daily; if needed, may increase dose gradually, usually once every 4 weeks, but not more frequently than once every 7 to 10 days; monitor blood pressure closely with each dose increase; usual effective dose: 30 to 120 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15546967','lexi-content-ref-Wigley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15546967','lexi-content-ref-Wigley.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Immediate release:<b> Note: </b>Only for short-term use in hospitalized patients with severe digital ischemia. Initial: 10 mg 3 times daily; may titrate by 10 mg increments as needed based on response and tolerability, up to 30 mg 3 times daily; transition to an ER formulation for maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15546967','lexi-content-ref-12324557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15546967','lexi-content-ref-12324557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d539b92-9744-40f5-b60b-099bf8be5b0f">Tocolysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tocolysis (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: Initial: 20 to 30 mg as a loading dose, followed by 10 to 20 mg every 3 to 8 hours for up to 48 hours; maximum dose: 180 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27661654','lexi-content-ref-Simhan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27661654','lexi-content-ref-Simhan.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991018"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (systemic clearance minimally affected by kidney dysfunction); however, use of lower initial doses and more frequent monitoring is recommended in severe impairment (eg, CrCl &lt;30 mL/minute) as these patients are more sensitive to nifedipine's BP lowering effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3987180','lexi-content-ref-3545614','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3987180','lexi-content-ref-3545614','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3757391','lexi-content-ref-4041333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3757391','lexi-content-ref-4041333'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary; however, use of lower initial doses and more frequent monitoring is recommended as these patients are more sensitive to nifedipine's BP lowering effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3757391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3757391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6625800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6625800'])">Ref</a></span>); however, use of lower initial doses and more frequent monitoring is recommended as these patients are more sensitive to nifedipine's BP lowering effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988232"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied); use with caution. Clearance of nifedipine is reduced in cirrhotic patients, which may lead to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.</p></div>
<div class="block doe drugH1Div" id="F201405"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Avoid immediate-release formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21518977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21518977'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F201425"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12643" href="/d/html/12643.html" rel="external">see "Nifedipine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="14516a2f-6888-41c0-b311-7e97dfaa91bf">Hypertension, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, severe:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use should be under the supervision of a specialist experienced in the management of pediatric hypertension in the inpatient tertiary setting and used only after other alternatives have been shown to be ineffective. Current pediatric blood pressure guidelines do not recommend nifedipine for the management of acute severe hypertension, as other safe and effective alternatives are available for use in the pediatric population (eg, hydralazine, isradipine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-12904113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-12904113'])">Ref</a></span>). If treatment with nifedipine is deemed appropriate and necessary, then administration should occur in the inpatient setting where blood pressure and other hemodynamic parameters can be closely monitored.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Immediate release: Oral: 0.04 to 0.25 mg/kg/dose; maximum single dose: 10 mg/dose; may repeat if needed every 4 to 6 hours; monitor carefully; maximum daily dose: 1 to 2 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11445791','lexi-content-ref-11793132','lexi-content-ref-22577545','lexi-content-ref-15054645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11445791','lexi-content-ref-11793132','lexi-content-ref-22577545','lexi-content-ref-15054645'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b> Limited data available: Children and Adolescents (able to swallow whole tablet): Extended release: Oral: Initial: 0.2 to 0.5 mg/kg/<b>day</b> once daily or divided in 2 doses every 12 hours; do not exceed initial adult daily dose of 30 to 60 mg/<b>day</b>; titrate dose to effect; maximum daily dose: 3 mg/kg/<b>day</b> up to 120 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-1681227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-1681227'])">Ref</a></span>); some centers use a higher maximum dose: 3 mg/kg/<b>day</b> up to 180 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11149130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11149130'])">Ref</a></span>). <b>Note:</b> In adults, doses are usually titrated upward over 7 to 14 days; may increase over 3 days if clinically necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5d99bf1-ceb9-4d3a-9f0b-85c7879d3777">High altitude pulmonary edema, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>High altitude pulmonary edema, treatment: </b> Limited data available: <b>Note:</b> Reserve treatment with NIFEdipine for unsatisfactory response to oxygen and/or altitude descent:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Oral: 0.5 mg/kg/dose every 8 hours; maximum dose: 20 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470103','lexi-content-ref-Otto.1','lexi-content-ref-11682018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470103','lexi-content-ref-Otto.1','lexi-content-ref-11682018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release (preferred if weight allows): Oral: 1.5 mg/kg/day once daily or divided in 2 doses per <b>day</b>; do not exceed adult dose of 30 mg every 12 hours. <b>Note:</b> Smallest extended-release dosage form available is 30 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470103','lexi-content-ref-Otto.1','lexi-content-ref-31248818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470103','lexi-content-ref-Otto.1','lexi-content-ref-31248818'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51196513"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied); the pharmacokinetics of nifedipine are not significantly influenced by the degree of renal impairment (only trace amounts of unchanged drug are found in urine). Based on experience in adult dialysis patients, supplemental doses are not necessary with hemodialysis or peritoneal dialysis; however, more frequent monitoring may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51196514"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied); use with caution. Clearance of nifedipine is reduced in cirrhotic adult patients, which may lead to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.</p></div>
<div class="block arsc drugH1Div" id="F55750586"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Angina/Myocardial infarction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exacerbation of angina pectoris</b> and/or <b>acute myocardial infarction</b> (MI) have occurred with initiation or dosage titration of immediate release (IR) (orally or sublingually) nifedipine. <b>Hypotension</b> and reflex <b>tachycardia</b> may occur resulting in angina and/or MI in patients with coronary heart disease, especially in the absence of concurrent beta-blockade. Use of IR nifedipine has been associated with increased mortality in patients with coronary heart disease. In patients with unstable angina/non–ST-elevation myocardial infarction (STEMI), the use of IR nifedipine is not recommended in the absence of a beta-blocker and is contraindicated in patients with STEMI. Effects may be reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-2857206','lexi-content-ref-7648682','lexi-content-ref-6365350','lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-2857206','lexi-content-ref-7648682','lexi-content-ref-6365350','lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Hypotension due to calcium channel blocking properties may cause a reflex increase in sympathetic activity, leading to ischemic effects. In addition, the IR nature of nifedipine may cause more marked fluctuations in hemodynamics compared to extended release (ER) formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7648682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7648682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; increase in mortality observed after 2 weeks (Muller 1984). However, hemodynamic effects (ie, decrease in blood pressure, increase in heart rate, ECG changes) observed as quickly as after 1 dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2857206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2857206'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Acute MI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6365350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6365350'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coronary heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7648682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7648682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Refractory angina (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2857206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2857206'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension/syncope</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Symptomatic <b>hypotension</b> with or without <b>syncope</b> may occur when using the immediate release (IR) formulation. The use of IR nifedipine (sublingually or orally) in hypertensive emergencies and urgencies is neither safe or effective and is associated with increased risk of adverse events such as acute myocardial infarction, cerebrovascular ischemia, fetal distress, and death when used to treat hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3632177','lexi-content-ref-8217985','lexi-content-ref-21849654','lexi-content-ref-15777455','lexi-content-ref-3827433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3632177','lexi-content-ref-8217985','lexi-content-ref-21849654','lexi-content-ref-15777455','lexi-content-ref-3827433'])">Ref</a></span>). IR nifedipine may be warranted for acute treatment in pregnant or postpartum women based on guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575639'])">Ref</a></span>). Although hypotension should be reversible upon discontinuation, effects may be initially severe and resistant to treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25515131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25515131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Inhibits calcium channels in peripheral smooth muscle leading to vasodilation. IR nifedipine, compared to extended release (ER) nifedipine has a much faster rate of increase in plasma levels, leading to more adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19337538']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19337538'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; hemodynamic effects (ie, decrease in blood pressure, increase in heart rate) observed as quickly as after one dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2857206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2857206'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (age 60 to 83 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2857206','lexi-content-ref-21849654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2857206','lexi-content-ref-21849654'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral edema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral edema</b> is a common adverse reaction of calcium channel blockers, characterized by ankle and leg swelling independent of fluid retention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11464254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11464254'])">Ref</a></span>). It is a bothersome adverse reaction for patients and may lead to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>). Peripheral edema can be expected to subside within several days following intervention.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; related to the pharmacologic action. Calcium channel blocker-mediated peripheral edema is caused by arteriolar vasodilation that subsequently leads to increased hydrostatic pressure in the precapillary circulation and fluid movement from the capillary vasculature to the interstitial space (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>). In addition, impaired postural vasoconstriction may contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11464254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11464254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; has been reported between 4 weeks to &gt;6 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose-related (ie, higher doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>); however, may develop more frequently and at lower doses in patients with impaired postural autoregulation (eg, diabetes, arterial disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11464254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11464254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration-related (&gt;6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dihydropyridine calcium channel blockers (DHPs) versus non-DHPs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lipophilic DHPs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21558959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21558959'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F201367"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence may include data with concomitant beta-blocker therapy. ER = extended release; IR = immediate release.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (IR: 25%; ER: &lt;3%), peripheral edema (4% to 30%)<span class="lexi-table-link-container"> (<a aria-label="Peripheral Edema table link" class="lexi-table-link" data-table-id="lexi-content-peripheral-edema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-peripheral-edema')">table 1</a>)</span><span class="table-link" style="display:none;">Peripheral Edema</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Peripheral Edema" frame="border" id="lexi-content-peripheral-edema" rules="all">
<caption style="text-align:center;">
<b>Nifedipine: Adverse Reaction: Peripheral Edema</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Nifedipine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nifedipine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">180 mg per day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120 mg per day or more</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">226</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">less than 60 mg per day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Heartburn (IR: ≤11%), nausea (IR: ≤11%; ER: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (IR: 27%), headache (16% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (IR: 12%; ER: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (4%), cardiac failure (2%), palpitations (≤7%), transient hypotension (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (IR), diaphoresis, pruritus, skin rash (ER), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (IR), abdominal pain (ER), constipation (≤3%), diarrhea, dyspepsia (ER), flatulence, xerostomia (ER)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (ER), sexual difficulty (IR)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Balance impairment (IR), chills (IR), drowsiness (ER), fatigue (ER: 6%), insomnia (ER), jitteriness (IR), mood changes (IR: ≤7%), nervousness (≤7%), pain (ER), paresthesia (ER), shakiness (IR), sleep disturbance (IR)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (ER), joint stiffness (IR), lower limb cramp (ER), muscle cramps (IR: ≤8%), tremor (IR: ≤8%; ER: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (IR)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (ER: &lt;3%; IR: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Chest congestion (IR), cough (IR: ≤6%; ER: &lt;1%), dyspnea, nasal congestion (IR), pleuritic chest pain (ER), pulmonary edema (2%), wheezing (IR: ≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, inflammation (IR)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, cardiac conduction disorder, erythromelalgia, exacerbation of angina pectoris, facial edema, hypotension (may be severe hypotension), syncope, tachycardia, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, exfoliative dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, gout, gynecomastia, hot flash, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, eructation, gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal irritation, gingival hyperplasia, melena, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, hematuria, mastalgia, nocturia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukopenia, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (allergic)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, ataxia, depression, hypertonia, hypoesthesia, malaise, migraine, nightmares, paranoid ideation, rigors, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (with positive ANA), back pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal lacrimation, periorbital edema, transient blindness (at peak of plasma level; can be unilateral), visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis, sinusitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Roujeau 1991, Tripathy 2009), bullous skin disease (Morimoto 2021), erythema multiforme (Bewley 1993), psoriasis (Song 2021), skin photosensitivity (Seggev 1996; Thomas 1986; Zenarola 1991), Stevens-Johnson syndrome (Stern 1989), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bezoar formation, gastrointestinal obstruction (Juurlink 2014), gastrointestinal ulcer (Lavy 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant neoplasm of lip (Friedman 2012), positive direct Coombs test</p></div>
<div class="block coi drugH1Div" id="F201381"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to nifedipine or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Considered contraindicated in patients with ST-elevation myocardial infarction (STEMI) (ACCF/AHA [O'Gara 2013]); avoid use (Elkayam 1990; FDA 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to other dihydropyridine calcium antagonists; severe hypotension; cardiovascular shock; concomitant use with rifampicin; breast-feeding; pregnancy or women of childbearing potential. Note: SOGC guidelines recommend nifedipine as a preferred agent for maternal hypertension (SOGC [Magee 2022]). Extended release only: Kock pouch (ileostomy after proctocolectomy); moderate or severe hepatic impairment; severe gastrointestinal obstructive disorders. Immediate release only: Acute myocardial infarction.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F201364"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: <b>IR nifedipine should not be used for acute BP reduction.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in myocardial ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI strictures: Alterations in GI anatomy (eg, severe GI narrowing, history of GI cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty) and underlying hypomotility disorders have led to bezoar formation with extended release forms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: The American College of Cardiology/American Heart Association heart failure guidelines recommend to avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (FDA 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Clearance of nifedipine is reduced in cirrhotic patients leading to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extended release formulation: Consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract (eg, severe gastrointestinal narrowing, colon cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty) has been associated with symptoms of obstruction (pharmacobezoar).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immediate release formulation: Immediate release formulations should not be used to manage primary hypertension, adequate studies to evaluate outcomes have not been conducted.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Adalat CC tablets contain lactose; do not use with galactose intolerance, congenital lactase deficiency, or glucose-galactose malabsorption syndromes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Use with caution before major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia may result in severe hypotension and/or increased fluid requirements. Consider withdrawing nifedipine (&gt;36 hours) before surgery if possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Abrupt withdrawal may cause rebound angina in patients with coronary artery disease.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53108550"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The "bite and swallow" method of administering immediate-release nifedipine is not recommended; variability of dose supplied via this method may lead to an overdose and result in significant side effects (eg, hypotension) in pediatric patients (Flynn 2003). An extemporaneous solution should be compounded to provide the most accurate dosing (see "Extemporaneous Preparations").</p></div>
<div class="block foc drugH1Div" id="F201374"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procardia: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adalat CC: 30 mg [DSC], 60 mg [DSC], 90 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procardia XL: 30 mg, 60 mg, 90 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg, 90 mg</p></div>
<div class="block geq drugH1Div" id="F201360"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F201384"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (NIFEdipine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.46 - $1.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.99 - $2.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (NIFEdipine ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.41 - $1.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $0.54 - $2.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $0.67 - $3.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (NIFEdipine ER Osmotic Release Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1.10 - $1.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1.83 - $3.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $2.31 - $2.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Procardia XL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $7.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $13.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $15.83</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867682"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adalat XL: 20 mg [DSC], 30 mg, 60 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg</p></div>
<div class="block adm drugH1Div" id="F201378"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: In general, may be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Tablets should be swallowed whole; do not crush, split, or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Adalat CC, Afeditab CR: Administer on an empty stomach (per manufacturer). Other extended release products may not have this recommendation; consult product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR capsule formulation is available. If safety and efficacy of nifedipine can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, selection of IR formulation or alternative therapy is advised for cardiovascular and other high-risk labeled and off-label indications.</p></div>
<div class="block admp drugH1Div" id="F52613422"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: In general, administer with or without food. If using extemporaneously compounded oral suspension, use calibrated device to accurately measure dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Tablets should be swallowed whole; do not crush, break, chew, or divide.</p></div>
<div class="block use drugH1Div" id="F201377"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina:</b> Management of chronic stable or vasospastic angina.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b> Management of hypertension (ER products only).</p></div>
<div class="block off-label drugH1Div" id="F25469158"><span class="drugH1">Use: Off-Label: Adult</span><p>Anal fissure; High-altitude pulmonary edema; Hypertensive emergency in pregnancy or postpartum (including acute-onset severe hypertension in preeclampsia/eclampsia); Pulmonary arterial hypertension, group 1; Raynaud phenomenon; Tocolysis</p></div>
<div class="block mst drugH1Div" id="F201456"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">NIFEdipine may be confused with niCARdipine, niMODipine, nisoldipine</p>
<p style="text-indent:-2em;margin-left:4em;">Procardia XL may be confused with Cartia XT</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Nifedipine (immediate release) is identified as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potential to cause hypotension and risk for precipitating myocardial ischemia (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Depin [India] may be confused with Depen brand name for penicillamine [US]; Depon brand name for acetaminophen [Greece]; Dipen brand name for diltiazem [Greece]</p>
<p style="text-indent:-2em;margin-left:4em;">Nipin [Italy and Singapore] may be confused with Nipent brand name for pentostatin [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F201443"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F201369"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May increase the serum concentration of NIFEdipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: NIFEdipine may enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Inhibitors of Equilibrative Nucleoside (ENT1) and Concentrative Nucleoside (CNT3) Transport Proteins may increase the serum concentration of Cladribine.  Management: Avoid concomitant use of ENT1 or CNT3 inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider an ENT1 or CNT3 inhibitor dose reduction and separation in the timing of administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of NIFEdipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of NIFEdipine. Management: Avoid coadministration of nifedipine with strong CYP3A4 inducers when possible and if combined, monitor patients closely for clinical signs of diminished nifedipine response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of NIFEdipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of NIFEdipine. Management: Consider alternatives to this combination when possible. If combined, initiate nifedipine at the lowest dose available and monitor patients closely for increased nifedipine effects and toxicities (eg, hypotension, edema).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: NIFEdipine may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: May increase the serum concentration of NIFEdipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of NIFEdipine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: NIFEdipine may decrease the serum concentration of QuiNIDine. NIFEdipine may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: NIFEdipine may increase the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): NIFEdipine may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F201395"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Nifedipine serum levels may be decreased if taken with food. Food may decrease the rate but not the extent of absorption of Procardia XL. Increased nifedipine concentrations resulting in therapeutic and vasodilator side effects, including severe hypotension and myocardial ischemia, may occur if nifedipine is taken by patients ingesting grapefruit. Management: Avoid grapefruit/grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F58529867"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Nifedipine is one of the medications patients can transition to if currently taking an agent that is ineffective or should be avoided during pregnancy (ACC/AHA [Whelton 2018]. ACOG 2019, NICE 2019).</p></div>
<div class="block pri drugH1Div" id="F201385"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nifedipine crosses the placenta (Mulrenin 2021; van de Vusse 2022).</p>
<p style="text-indent:0em;margin-top:2em;">An increase in perinatal asphyxia, cesarean delivery, prematurity, and intrauterine growth restriction have been reported following maternal use (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019a).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of nifedipine may be altered. Close monitoring is recommended (Mulrenin 2021; van de Vusse 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment for chronic hypertension is initiated during pregnancy, long-acting oral nifedipine is one of the preferred agents; avoid in patients with tachycardia (ACOG 2019a; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]). IR oral nifedipine is recommended for the management of acute-onset, severe hypertension in pregnant and postpartum patients, including those with preeclampsia or eclampsia (ACOG 2020; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">IR oral nifedipine has also been evaluated for the treatment of preterm labor. Tocolytics may be used for the short-term (48-hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG 2016). Nifedipine is ineffective for maintenance tocolytic therapy (ACOG 2016; Aggarwal 2018; Roos 2013; Verspyck 2017).</p></div>
<div class="block brc drugH1Div" id="F21123179"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Nifedipine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Multiple reports summarize data related to the presence of nifedipine in breast milk:</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk was sampled in a patient following a full-term delivery who received nifedipine 10 mg/day prior to the study. Nifedipine 20 mg was administered on the day of the study at 10 days postpartum. Nifedipine and the pyridine metabolite were present in breast milk. Peak concentrations occurred ~1 hour following the maternal dose (Penny 1989).</p>
<p style="text-indent:-2em;margin-left:4em;">• Following delivery at 26 weeks gestation, breast milk was sampled in a patient who received nifedipine 30 mg every 8 hours for 48 hours, followed by nifedipine 20 mg every 8 hours for 48 hours, then 10 mg every 8 hours for 36 hours. The highest breast milk concentration (53.35 ng/mL) occurred within 1 hour of the 30 mg dose. The highest breast milk concentrations following the 20 mg and 10 mg doses were 16.35 ng/mL and 12.89 ng/mL, respectively. Nifedipine was measurable in breast milk 8 hours following the 20 mg and 30 mg doses, but not the 10 mg dose. The reported half-life of nifedipine in breast milk was ~3 hours (Ehrenkranz 1989).</p>
<p style="text-indent:-2em;margin-left:4em;">• Using a milk concentration of 53.35 ng/mL, the estimated daily infant dose of nifedipine via breast milk is 8 mcg/kg/day providing a relative infant dose (RID) of 0.27% to 3.2% compared to an infant therapeutic dose of 0.25 to 3 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• In addition to maternal dose, breast milk concentrations may be influenced by maternal ABCG2 genotype. Nifedipine is a substrate to ABCG2 transporter which is expressed on lactating breasts. Patients genotyped as wild-type homozygous 421CC (n=13) had lower breast milk concentrations of nifedipine than patients genotyped as 421CA heterozygous (n=6) following a maternal dose of slow-release nifedipine 20 mg administered 15 to 30 days postpartum (Malfará 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">The use of nifedipine in breastfeeding patients for the treatment of Raynaud phenomenon has been described in case reports and case series; no adverse events were noted in the infants exposed to nifedipine via breast milk (Anderson 2004; Barrett 2013; Garrison 2002; Jansen 2019; Page 2006; Wu 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Nifedipine is considered compatible with breastfeeding (ESC [Cífková 2020]; SOGC [Magee 2022]; WHO 2002), although data following long-term use is limited (WHO 2002). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">The Academy of Breastfeeding Medicine recommends the use of nifedipine for the treatment of Raynaud phenomenon of the nipple in breastfeeding mothers (ABM [Berens 2016]).</p></div>
<div class="block dic drugH1Div" id="F201387"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit juice with all products.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Capsule is rapidly absorbed orally if it is administered without food, but may result in vasodilator side effects; if flushing is problematic, administration with low-fat meals may decrease. In general, can take with or without food.</p></div>
<div class="block mop drugH1Div" id="F201372"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate; blood pressure; peripheral edema.</p></div>
<div class="block pha drugH1Div" id="F201363"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina; also reduces peripheral vascular resistance, producing a reduction in arterial blood pressure.</p></div>
<div class="block phk drugH1Div" id="F201380"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Immediate release: ~20 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding (concentration dependent): 92% to 98%; <b>Note:</b> Protein-binding may be significantly decreased in patients with renal or hepatic impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 to inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Capsule: 40% to 77%; ER: 65% to 89% relative to immediate release capsules; bioavailability increased with significant hepatic disease</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults: Healthy: 2 to 5 hours; Cirrhosis: 7 hours; Elderly: 7 hours (extended release tablet)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60% to 80% as inactive metabolites); feces</p></div>
<div class="block phksp drugH1Div" id="F51154897"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Mean C<sub>max</sub> is 36% higher and plasma concentration is 70% greater in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F201388"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Coracten | Epilat | Fenamon | Nifecard | Zenusin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Nifecor | Nifed sol | Nifedel | Nifedipina | Nifedipina r 20 | Nifelat | Nifenitron | Nitenk</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Fedip | Majolat | Nifebene | Nifedipin stada artzneimittel | Nifedipin-genericon pharma | Nifehexal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adapine | Addos xr | Adefin | Adefin xl | Apo-Nifedipine XR | Chemmart Nifedipine | Cm nifedipine | Nifecard | Nifedipine-bc | Nifehexal | Nyefax | Sbpa nifedipine | Terry White Chemists Nifedipine | Tw nifedipine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ampine | Fenamon | Ficard | Nefelon | Nicodin | Nidipine | Nifecap | Nifecard | Nifedin | Nificap | Nifin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Hypan | Nifedipine doc | Nifedipine eg | Nifedipine mylan | Nifedipine ratiopharm | Nifeslow</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalate la | Arconifed sr | Nifcal | Nifedi denk 10 retard | Nifedi denk 20 retard | Nifedipine lp tm</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat Eins | Adalat oros | Cordaflex | Cordipin xl | Corinfar | Korincare | Korincare neo | Nifedipin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Adalex | Adcor | Cardalin | Cronodipin | Dilaflux | Dilavax | Dipinal | Loncord | Neo fedipina | Nifadil | Nifedax | Nifedicard | Nifedipress | Nifehexal | Nioxil | Normopres | Oxcord</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Cardipin | Corotrend | Ecodipin | Nife-basan | Nifedipin "genericon" | Nifedipin Helvepharm | Nifedipin mepha | Nifedipin Sandoz | Nifedipin spirig | Nifedipin spirig hc | Nifedipin upsa</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Adalat la | Adalate | Apo nifedipine | Arconifed sr | Nifesha</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Angiodisten | Carbloc | Cardicon | Nifedipino | Nifedipino L.Ch. | Nipress | Nipress Oad | Pabalat | Sulotil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Adalat | De gao ning | Ecodipin | Er kang bi tong | Heng xin | Jiu bao ka di | Jiu bao ping | Jupocardia | Na xin tong | Ni fu da | Nifedipin ratiopharm | Nifedipine extended release tablets (iii) | Nifedipine sustained release tablets (i) | Nifedipine sustained release tablets (ii) | Nifedipine sustained release tablets (iii) | Nifedipine sustained release tablets (iv) | Sai yan teng | Sheng tong ping | Tian hai li | Xin ran | Yi xin | Yi xin ping</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acerdil 24 horas | Adalat | Adalat cc | Adalat oros | Beclazone | Cardiosol | Nicaloc | Nifecor | Nifedipina | Nifedipino | Nifetabs | Nifevas-O | Tensomax | Tensopin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Apo nifed | Cordafen | Cordipin | Cordipin xl | Corinfar | Coronipin | Depin e | Nifecard | Nifehexal | Pidilat | Sponif | Supracordin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalate | Aprical | Cisday | Coracten | Cordicant | Corinfar | Corotrend | Dignokonstant | Duranifin | Jedipin | Jutadilat | Nife | Nife biochemie | Nife klast | Nife wolff | Nife-puren | Nifeclair | Nifecor | Nifedipat | Nifedipin | Nifedipin al | Nifedipin denk | Nifedipin Sandoz | Nifedipin stada | Nifedipin Verla | Nifehexal | Nifelat | Nifical | Nifsigma | Pidilat</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Adalat oros | Nifedipin alternova</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Cardiomed | Corapres | Dilcor | Evopril sr | Fusepina | Lufradipina | Nicardia xl | Nifecol | Nifed | Nifedicor | Nifedilat | Nifedip | Nifedipina | Nifedipina alfa | Nifedipina Inmenol | Nifedipina Lam | Nifedipina retard lam | Nifedipino | Nifedipres | Nifek | Nifelac | Nificard | Nifpin AP | Nitensor | Presnife retard 30 | Presnife retard 60 | Tensopin | Unifedipina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Nifedin | Nifedipina | Nifedipino | Nifelan | Zenusin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat crono | Adalat oros | Cordafen | Cordaflex | Cordipin | Cordipin xl | Corinfar | Nifangin | Nifebene | Nifecard | Nifedeks | Nifedipin | Nifedipin ratiopharm | Nifedipina mylan | Nifehexal | Nifesan | Nifetard | Niphedipin | Nycopin | Nycopin depo | Phenihydin | Sanfidipin | Sponif</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Cardiopine | Dilcor | Epilat | Epilat retard | Nifepin | Vasonipine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Cordilan | Dilcor | Nifedipino bayvit | Nifedipino ratiopharm | Pertensal</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Depin e retard | Epilat retard | Nifedi denk 10 retard | Nifedi denk 20 retard</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Coronipin | Enilevol | Nical | Nifangin | Nifdemin | Nifecor | Nifedipin alternova | Onidin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adalate | Chronadalate | Nifedipine Arrow | Nifedipine eg | Nifedipine g gam | Nifedipine gnr | Nifedipine merck | Nifedipine ratiopharm | Nifedipine rpg | Nifedipine sandoz | Nifedipine teva | Nifedirex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adanif | Adipine | Adipine mr | Angiopine | Calanif | Calchan mr | Calcilat | Cardilate mr | Cardiofin | Coracten | Coroday | Dexipress MR 20 | Fortipine | Fortipine la | Fortipine nye | Genalat | Hypolar | Kentipine | Nidef | Nifedipine Arrow | Nifedipine berk | Nifedipine cox | Nifedipine kent | Nifedipine sandoz | Nifedipress | Nifedipress berk | Nifedipress cox | Nifedipress sandoz | Nifedotard | Nifelease | Nifensar | Nifopress | Nimodrel | Nivaten | Slofedipine | Tensipine MR | Unipine xl | Valni | Vasad</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Cardigen retard | Ndip | Ndip xr | Nifedose | NIFIN 20 R | Novodep | Pinek | Pinfed sr | Retardine XL | Vl nifedipine | Vynif</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Antiblut | Coracten | Flecor n | Glopir | Macorel | Nefelid | Nifedicor | Nifedipat | Nifedipin al | Nifelat | Viscard</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Apo nifedipine | Cardilate mr | Carditas | Coracten | Cordipin | Nadipinia | Nifecard | Nifecard xl | Nifelat | Nifopress | Vasdalat | Waridipin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cordipin | Nifedipin | Nifedipin Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Cordaflex | Cordipin xl | Corinfar | Huma-nifedin | Nidipin | Nifecard xl | Nifedipin al</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Calcianta | Calcigard | Carvas | Cordalat | Coronipin | Farmalat | Fedipin | Ficor | Inficard | Nifecard | Nifedin | Pincard | Vasdalat | Vasoner | Xepalat | Zendalat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adanif | Adefin xl | Coracten | Nifed | Nifelease | Nifensar | Systepin | Tensipine MR | Vasofed</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Megalat | Nifedilong | Nifedipine teva | Pressolat</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Alnipine | Calbloc | Calcigard | Calnif | Cardipin | Cardovasc xl | Cardules | Depicor | Depin | Dolocard | Myogard | Myogard la | Nacten | Needin | Nepin | Nexidin | Nf | Nfd retard | Nicardia | Nicardia retard | Nifed | Nifedine | Nifelat | Niferil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat a.r. | Adalat crono | Citilat | Coral | Euxat | Fenidina | Nifedicor | Nifedicron | Nifedin | Nifedipina | Nifedipina doc | Nifedipina eg | Nifedipina mylan generica | Nifedipina provvisoria | Nifesal | Nipin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Coracten | Epilat | Fenamon | Myogard | Nifecard</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Adalat | ADALAT CR | Allotop l sawai | Allotop l tsumura | Alonix s | Anpect | Atanaal mita | Atanaal sawai | Atanaal towa | Atenerate kaken | Atenerate l mita | Atenerate merck hoei | Atenerate tsuruhara | Cardiobren | Cardioluft l | Cardioluft l fuji | Casanmil | Casanmil s | Celebrate | Cobalat | Cobalate kobayashi kako | Corinael | Corodilate | Emaberin | Emaberin l | Herlat | Kepakuru l | Kisalart hexal | Kisalart nichiiko | Knoramin | Knoramin chemiphar | Lemar | Marivolon | Menoprizin l | Milfadin | Moderat | Nalicidin | Nerabole kotobuki | Nerabole zeria | Nifedipine fujimoto | Nifedipine Kyorin Rimedio | Nifedipine L | Nifedipine merck hoei | Nifedipine mylan | Nifedipine nichiiko | Nifedipine teva | Nifedipine tsuruhara | Nifedipine yoshindo | Nifelanterin cr | Nifelantern | Nifelat | Nifelat l | Nifeplan L | Nifeslow | Nifpine | Nirena | Palpeat kyowa hakko | Palpeat pfizer | Ramitalate | Ramitalate taiyo | Ramitalate towa | Ramitalate-L | Ramitlalate l kayaku | Ronian | Sepamit | Siopelmin l | Towarat | Towarat l</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat la | Calcigard retard | Carditas retard | Depin e retard | Epilat retard | Nefdin | Nefin er | Nepif retard | Nepin sr | Nicardia | Nicardin sr | Nifecard xl | Nifed retard | Nifedi denk | Nifelat r | Nifelat retard | Nifpine retard | Nipine sr | Zenusin 20 sr</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Adapine osmo | Caranta | Dongkoo nifedipine | Fedipine 24 | Hadipine | Hawon nifedipine | Medicoret | Nadipine | Neprin | Nifedin | Nifedipinaeuderma | Nifedix | Nifedsol | Nifel | Nifelan | Nifendal | Niferon | Niferon cr | Nipidin | Nipine | Niporin | Pidipin | Sanodipine | Union nifedipine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Coracten | Zenusin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Apo nifed | Dilcor | Nifedicor | Nifedip | Nifelat | Nifelat r | Niferetard | Nipin | Zenusin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Apo nifed | Calcigarde | Cordafen | Cordaflex | Cordipin | Corinfar | Coronipin | Depin e | Nifadil | Nifebene | Nifecard | Nifedeks | Nifedipin | Nifedipin al | Nifedipin ratiopharm | Nifedipin stada | Nifedipin stada uno | Nifehexal | Nifesan | Phenihidin | Sanfidipin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Aprical | Hypan | Nifedipine mylan | Nifehexal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Calcigarde | Cordafen | Cordipin | Corinfar | Coronipin | Depin e | Duranifin | Fenamon | Nifadil | Nifecard | Nifedex | Nifedipin | Nifesan | Night rest | Phenihidin | Sanfidipin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Adalate | Apo nifed | Chronadalate | Coracten | Nifedicor | Nifegen | Pharmadipine | Servidipine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Anhiten a | Apo-fidipisal | Cordilat | Corogal | Corotrend | Difepar | Fusepina | Gelprim | Kabloc | Linam | Nifar | Nifar gb | Nifedigel | Nifedipino | Nifedipino bruluart | Nifedipino gi | Nifedipino gi serr | Nifedipino hispanoamericano | Nifedipino protein | Nifezzard | Nifser | Notinzalten | Noviken LP | Pidef</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adifen | Calcigard | Cordipin | Fenamon | Nicardia xl | Nifecard | Nifecip | Nifedipin | Nifehexal | Nifehexal retard | Nifelat | Niferin sr | Nudipin | Servidipine | Uphadipine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acefex | Adalat la | Adopine | Cardipin | D glopa nifedipine | Eglofedipine | Epnif retard | Eufedipine | Exus nifedipine | Fladipine retard | Glopir retard | Hartipin | Jamcelia nifedipine | Lifeback nifedipine retard | Macfedipine | Milton nifedipine | Myolax | Nicardia xl | Nifebond | Nifecard xl | Nifecure | Nifedin dexcel | Nifetab | Normodipin | Orfedipine | Patuo sr | Rebok nifedipine | Replek nifedipine retard | Scrip nifedipine | Topnife | Transglobe nifedipine | Zenusin 20 sr | Zibadipin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Adalate | Nifedipin abz | Nifedipin acis | Nifedipin al | Nifedipine A | Nifedipine accord | Nifedipine merck | Nifedipine PCH | Nifedipine ratiopharm | Nifedipine sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adalat | ADALAT CR | Adalat crono | Adalat la | Adalat oros | Adalat unimedic | Adalat xl | Nifedipin | Nifedipin al | Nifedipin ratiopharm | Nifedipine cf | Nifedipine sandoz | Nifenova | Nycopin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adefin xl | Arrow nifedipine | Nyefax | Tensipine MR</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Angidex | Fediral | Nifedipino | Nifedipino genfar | Nifensar | Nifepharm | Tensomax | Unipine xl</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Angipine | Calcibloc | Calcicor | Calgina | Cardicap | Darat | Denkifed | Fedcor | Fedipin | Hartigard | Heblopin | Heblopine | Hyperten | Nelapine | Nicardia | Nicardia xl | Nifecar | Nifedipine Medicap | Nifedipine Pacific | Nifelan | Nifestad | Normadil | Odipin | Servidipine | Tensibloc</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Anifed | Caranta | Cardipine | Masdipine sr | Nidipine | Nifecard | Nifed | Nifedi denk | Nifedicor | Nifedil | Nifelat | Ronian</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Cordafen | Cordipin | Corinfar | Nifecard | Nifedicor | Nifedipin acis | Nifedipin al | Nifedipin ratiopharm | Nifehexal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Afeditab CR | Nifediac CC | Nifedical | Nifedipine er | Procardia</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat a.p. | Besdipina | Corinfar | Nifedate | Nifedipina | Nifedipina Generis | Nifedipina ratiopharm | Zenusin 20 sr</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Cuorex retard | Nifedil a.r. | Nifeten | Nifeten retard | Tensimeg | Tensoprel retard</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat LA | Adalat Retard | Epilat | Epilat Retard | Myogard</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Cordafen | Cordipin | Corinfar | Epilat retard</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Calcigard | Calcigard retard | Calcigarde | Carinfer | Cordafen | Cordaflex | Cordipin | Cordipin xl | Corinfar | Corinfar retard | Fenamon | Nicardia | Nicardia cd retard | Nifebene | Nifecard | Nifecard xl | Nifedex | Nifedicap | Nifedipin | Nifedipin ns | Nifedipin-fpo | Nifedipine akrihin | Nifedipine mik | Nifehexal | Nifelat | Nifesan | Nificard | Osmo adalat | Phenihidin | Vero nifedipin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Apo nifedipine | Epilat | Nifecard</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Apo nifed | Cardiolat | Cordipin | Cordipin xl | Depin e retard | Fenamon | Nifecard | Nifedi denk | Nifedipine la | Nipin | Vasdalat</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Cordipin | Nifecard</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cordafen | Cordipin | Cordipin xl | Corinfar | Nifecard | Nifehexal | Sponif</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adipine | Apo nifed | Calcigard | Carnif | Coracten | Depin e retard | Fenamon | Jedipin | Nelapine | Nicaloc | Nicardia | Nicardia cd | Nifecard | Nifedi denk | Nifedipin stada | Nifedipine ratiopharm | Nifelat | Nifelat r | Nifelat-q | Nificard | Nifiran | Niufedepine | Nyefax | Servidipine | Stada Uno | Towarat | Zenusin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adalate | Anifed | Coracten | Corinfar | Nifedicor | Nifepine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat crono | Kardilat | Nidicard | Nidilat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat cc | Adalat oros | Adapine | Ajulate | Alat | Alonix s | Apo nifed | Atanaal | Badipine | Cardiobren | Citilat | Coracten | Coral | Coronipin | Dekalat | Emaberin | Fedipine | Fenamon | Glopir | Harwell | Memoprizin | Nedipin | Neocardia | Nidepin | Nidomate | Nifate | Nifecardia | Nifed | Nifedin | Nifehexal | Nifelan | Nifelat | Nifepine | Niferos oros | Nirena | Nisimlone | Nisipin | Nit | Palpeat | Posipin | Ronian | Servidipine | Sidalat | Sindipine | Towarat</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Cordafen | Cordaflex | Cordipin | Cordipin retard | Cordipin xl | Corinfar | Corinfar retard | Epilat | Fenamon | Nicardia | Nifecard | Nifedicap | Nifedipin | Nifelat | Osmo adalat | Phenihidin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Adalat la | Agopine | Calcigard retard | Carditas retard | Fenamon sr | Nepin sr | Nicardia | Nifedi denk 20 retard | Nifelat | Nifelat retard</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Ciruton | Cordipin | Cuorex | Ficarel | Nifed sol | Nifedel | Nifedilat | Nifedin | Nifedipina | Novodipen | Tonacor</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Adalat oros | Cardiosol | Conducil | Fedilex | Nifal | Nifebiopina | Nifedicor retard | Nifedipina | Nifedipina lp | Nifedipino | Nioxil | Tensodiam | Tensomax | Tensopin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Nifedipin hasan | Nifehexal 30 la | Nifephabaco | Pymenife</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adalat | Anginor-20 cr | Apo nifedipine | Bio nifedipine xl | Cardifen | Cardilat | Cipalat | Fedaloc | Gitsalat | Macorel | Nifedalat | Norton-nifedipine | Rolab-nifedipine | Spec nifedipine | Vascard</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Calcigard | Calnif | Cardifen | Carditas retard | Nifedi denk | Nifelat | Nipine sr</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Adalat xl | Calcigard retard | Nifelat</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AdalatXL.1">
<a name="AdalatXL.1"></a>Adalat XL (nifedipine extended release tablet) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11826214">
<a name="11826214"></a>Adcock KG, Wilson JT. Nifedipine Labeling Illustrates the Pediatric Dilemma for Off-Patent Drugs. <i>Pediatrics</i>. 2002;109(2):319-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11826214/pubmed" id="11826214" target="_blank">11826214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28784001">
<a name="28784001"></a>Aggarwal A, Bagga R, Girish B, Kalra J, Kumar P. Effect of maintenance tocolysis with nifedipine in established preterm labour on pregnancy prolongation and neonatal outcome. <i>J Obstet Gynaecol</i>. 2018;38(2):177-184. doi:10.1080/01443615.2017.1331340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/28784001/pubmed" id="28784001" target="_blank">28784001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24035211">
<a name="24035211"></a>Agrawal V, Kaushal G, Gupta R. Randomized controlled pilot trial of nifedipine as oral therapy vs. topical application in the treatment of fissure-in-ano. <i>Am J Surg</i>. 2013;206(5):748-751. doi:10.1016/j.amjsurg.2013.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24035211/pubmed" id="24035211" target="_blank">24035211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27661654">
<a name="27661654"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 171: Management of preterm labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi:10.1097/AOG.0000000000001711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/27661654/pubmed" id="27661654" target="_blank">27661654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443079">
<a name="32443079"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 222: Gestational hypertension and preeclampsia. <i>Obstet Gynecol</i>. 2020;135(6):e237-e260. doi:10.1097/AOG.0000000000003891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/32443079/pubmed" id="32443079" target="_blank">32443079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019a;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575639">
<a name="30575639"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 767: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2019b;133(2):e174-e180. doi:10.1097/AOG.0000000000003075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/30575639/pubmed" id="30575639" target="_blank">30575639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15060268">
<a name="15060268"></a>Anderson JE, Held N, Wright K. Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding. <i>Pediatrics</i>. 2004;113(4):e360-364. doi:10.1542/peds.113.4.e360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15060268/pubmed" id="15060268" target="_blank">15060268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15339869">
<a name="15339869"></a>Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). <i>Circulation</i>, 2004, 110(9):e82-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15339869/pubmed" id="15339869" target="_blank">15339869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation.</i> 2011;123(21):2434-2506. doi:10.1161/CIR.0b013e31821daaf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-August.1">
<a name="August.1"></a>August P. Treatment of hypertension in pregnant and postpartum patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23682366">
<a name="23682366"></a>Barrett ME, Heller MM, Stone HF, Murase JE. Raynaud phenomenon of the nipple in breastfeeding mothers: an underdiagnosed cause of nipple pain. <i>JAMA Dermatol.</i> 2013;149(3):300-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23682366/pubmed" id="23682366" target="_blank">23682366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1922223">
<a name="1922223"></a>Bärtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. <i>N Engl J Med</i>. 1991;325(18):1284-1289. doi: 10.1056/NEJM199110313251805.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1922223/pubmed" id="1922223" target="_blank">1922223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26881962">
<a name="26881962"></a>Berens P, Eglash A, Malloy M, Steube AM. ABM clinical protocol #26: persistent pain with breastfeeding. <i>Breastfeed Med</i>. 2016;11(2):46-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/26881962/pubmed" id="26881962" target="_blank">26881962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3632177">
<a name="3632177"></a>Bertel O. Symptomatic hypotension induced by nifedipine. <i>Arch Intern Med</i>. 1987;147(9):1683-1684.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/3632177/pubmed" id="3632177" target="_blank">3632177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8369687">
<a name="8369687"></a>Bewley AP, Feher MD, Staughton RC. Erythema multiforme following substitution of amlopidine for nifedipine. <i>BMJ</i>. 1993;307(6898):241. doi:10.1136/bmj.307.6898.241-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8369687/pubmed" id="8369687" target="_blank">8369687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11445791">
<a name="11445791"></a>Blaszak RT, Savage JA, Ellis EN. The use of short-acting nifedipine in pediatric patients with hypertension. <i>J Pediatr</i>, 2001;139(1):34-37. doi: 10.1067/mpd.2001.114699.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11445791/pubmed" id="11445791" target="_blank">11445791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bleday.1">
<a name="Bleday.1"></a>Bleday R. Anal fissure: Medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2857206">
<a name="2857206"></a>Boden WE, Korr KS, Bough EW. Nifedipine-induced hypotension and myocardial ischemia in refractory angina pectoris. <i>JAMA</i>. 1985;253(8):1131-1135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2857206/pubmed" id="2857206" target="_blank">2857206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al, “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,” <i>JAMA</i>, 2003, 289(19):2560-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9063228">
<a name="9063228"></a>Deen-Duggins L, Fry HR, Clay JR, Turner JR. Nifedipine-associated gingival overgrowth: a survey of the literature and report of four cases. <i>Quintessence Int.</i> 1996;27(3):163-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/9063228/pubmed" id="9063228" target="_blank">9063228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22441082">
<a name="22441082"></a>Deshwal R, Iqbal M, Basnet S. Nifedipine for the treatment of high altitude pulmonary edema. <i>Wilderness Environ Med</i>. 2012;23(1):7-10. doi: 10.1016/j.wem.2011.10.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22441082/pubmed" id="22441082" target="_blank">22441082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6637932">
<a name="6637932"></a>Dilmen U, Cagfülar MK, Senses A, et al, “Nifedipine in Hypertensive Emergencies of Children,” <i>Am J Dis Child</i>, 1983, 137(12):1162-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/6637932/pubmed" id="6637932" target="_blank">6637932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11793132">
<a name="11793132"></a>Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S. Evaluation of the safety of short-acting nifedipine in children with hypertension. <i>Pediatr Nephrol.</i> 2002;17(1):35-40. doi: 10.1007/s004670200006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11793132/pubmed" id="11793132" target="_blank">11793132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2921695">
<a name="2921695"></a>Ehrenkranz RA, Ackerman BA, Hulse JD. Nifedipine transfer into human milk. <i>J Pediatr.</i> 1989;114(3):478-480. doi:10.1016/s0022-3476(89)80579-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2921695/pubmed" id="2921695" target="_blank">2921695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2242521">
<a name="2242521"></a>Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. <i>Circulation</i>. 1990;82(6):1954-1961.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2242521/pubmed" id="2242521" target="_blank">2242521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12794583">
<a name="12794583"></a>Ezri T, Susmallian S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure. <i>Dis Colon Rectum</i>. 2003;46(6):805-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/12794583/pubmed" id="12794583" target="_blank">12794583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166210">
<a name="23166210"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in <i>Circulation</i>. 2014;129(16):e462]. <i>Circulation</i>. 2012;126(25):3097-3137. doi: 10.1161/CIR.0b013e3182776f83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23166210/pubmed" id="23166210" target="_blank">23166210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12904113">
<a name="12904113"></a>Flynn JT. Safety of short-acting nifedipine in children with severe hypertension. <i>Expert Opin Drug Saf</i>. 2003;2(2):133-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/12904113/pubmed" id="12904113" target="_blank">12904113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3). doi: 10.1542/peds.2017-1904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11149130">
<a name="11149130"></a>Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. <i>Pediatr Nephrol</i>, 2000;15(3-4):302-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11149130/pubmed" id="11149130" target="_blank">11149130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22869299">
<a name="22869299"></a>Friedman GD, Asgari MM, Warton EM, Chan J, Habel LA. Antihypertensive drugs and lip cancer in non-Hispanic whites. <i>Arch Intern Med.</i> 2012;172(16):1246-1251. doi: 10.1001/archinternmed.2012.2754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22869299/pubmed" id="22869299" target="_blank">22869299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7648682">
<a name="7648682"></a>Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. <i>Circulation</i>. 1995;92(5):1326-1331. doi:10.1161/01.cir.92.5.1326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/7648682/pubmed" id="7648682" target="_blank">7648682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gallagher.1">
<a name="Gallagher.1"></a>Gallagher SA, Hackett P. High-altitude pulmonary edema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30742570">
<a name="30742570"></a>Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologist and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary [published correction appears in <i>Endocr Pract</i>. 2019;25(2):204]. <i>Endocr Pract</i>. 2019;25(1):69-100. doi:10.4158/CS-2018-0535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/30742570/pubmed" id="30742570" target="_blank">30742570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12449056">
<a name="12449056"></a>Garrison CP. Nipple vasospasms, Raynaud's syndrome, and nifedipine. <i>J Hum Lact</i>. 2002;18(4):382-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/12449056/pubmed" id="12449056" target="_blank">12449056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. <i>Hypertension</i>. Published online November 15, 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315243">
<a name="22315243"></a>Goundry B, Bell L, Langtree M, Moorthy A. Diagnosis and management of Raynaud's phenomenon. <i>BMJ.</i> 2012;344:e289. doi:10.1136/bmj.e289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22315243/pubmed" id="22315243" target="_blank">22315243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7621029">
<a name="7621029"></a>Harel-Raviv M, Eckler M, Lalani K, Raviv E, Gornitsky M. Nifedipine-induced gingival hyperplasia. A comprehensive review and analysis. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod.</i> 1995;79(6):715-722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/7621029/pubmed" id="7621029" target="_blank">7621029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hopkins.1">
<a name="Hopkins.1"></a>Hopkins W, Rubin LJ. Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. <i>Eur Heart J.</i> 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8217985">
<a name="8217985"></a>Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. <i>Br J Obstet Gynaecol</i>. 1993;100(10):959-961. doi:10.1111/j.1471-0528.1993.tb15120.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8217985/pubmed" id="8217985" target="_blank">8217985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. Published online December 18, 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30969221">
<a name="30969221"></a>Jansen S, Sampene K. Raynaud phenomenon of the nipple: an under-recognized condition. <i>Obstet Gynecol</i>. 2019;133(5):975-977.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/30969221/pubmed" id="30969221" target="_blank">30969221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21849654">
<a name="21849654"></a>Jung SY, Choi NK, Kim JY, et al. Short-acting nifedipine and risk of stroke in elderly hypertensive patients. <i>Neurology</i>. 2011;77(13):1229-1234. doi:10.1212/WNL.0b013e318230201a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/21849654/pubmed" id="21849654" target="_blank">21849654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Juurlink.1">
<a name="Juurlink.1"></a>Juurlink DN, Hellings C, Gomes T, et al. Extended-release nifedipine and the risk of intestinal obstruction: a population-based study. <i>BMJOpen</i>. 2014;4:e005377. doi:10.1136/bmjopen-2014-005377</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25515131">
<a name="25515131"></a>Khoo F, Mathur M. Severe resistant maternal hypotension following tocolysis with nifedipine. <i>BMJ Case Rep</i>. 2014;2014:bcr2014208059. doi:10.1136/bcr-2014-208059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/25515131/pubmed" id="25515131" target="_blank">25515131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int.</i> 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3545614">
<a name="3545614"></a>Kleinbloesem CH, van Brummelen P, Breimer DD. Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.<i> Clin Pharmacokinet.</i> 1987;12(1):12-29. doi:10.2165/00003088-198712010-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/3545614/pubmed" id="3545614" target="_blank">3545614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3987180">
<a name="3987180"></a>Kleinbloesem CH, van Brummelen P, van Harten J, Danhof M, Breimer DD. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. <i>Clin Pharmacol Ther.</i> 1985;37(5):563-574. doi:10.1038/clpt.1985.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/3987180/pubmed" id="3987180" target="_blank">3987180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3757391">
<a name="3757391"></a>Kleinbloesem CH, van Brummelen P, Woittiez AJ, Faber H, Breimer DD. Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. <i>Clin Pharmacokinet.</i> 1986;11(4):316-322. doi:10.2165/00003088-198611040-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/3757391/pubmed" id="3757391" target="_blank">3757391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18493524">
<a name="18493524"></a>Lavy A. Corrosive effect of nifedipine in the upper gastrointestinal tract. <i>Diagn Ther Endosc</i>. 1999;6(1):39-41. doi:10.1155/DTE.6.39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/18493524/pubmed" id="18493524" target="_blank">18493524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470103">
<a name="29470103"></a>Liptzin DR, Abman SH, Giesenhagen A, Ivy DD. An approach to children with pulmonary edema at high altitude. <i>High Alt Med Biol</i>. 2018;19(1):91-98. doi:10.1089/ham.2017.0096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/29470103/pubmed" id="29470103" target="_blank">29470103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3221006">
<a name="3221006"></a>Lopez-Herce J, Albajara L, Cagigas P, et al, “Treatment of Hypertensive Crisis in Children With Nifedipine,” <i>Intensive Care Med</i>, 1988, 14(5):519-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/3221006/pubmed" id="3221006" target="_blank">3221006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31248818">
<a name="31248818"></a>Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. <i>Wilderness Environ Med</i>. 2019;30(4S):S3-S18. doi:10.1016/j.wem.2019.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/31248818/pubmed" id="31248818" target="_blank">31248818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25498261">
<a name="25498261"></a>Luks AM, McIntosh SE, Grissom CK, et al; Wilderness Medical Society. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. <i>Wilderness Environ Med</i>. 2014;25(4 suppl):S4-S14. doi:10.1016/j.wem.2014.06.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/25498261/pubmed" id="25498261" target="_blank">25498261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management.<i> J Obstet Gynaecol Can.</i> 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21558959">
<a name="21558959"></a>Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. <i>J Hypertens</i>. 2011;29(7):1270-1280. doi:10.1097/HJH.0b013e3283472643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/21558959/pubmed" id="21558959" target="_blank">21558959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30659932">
<a name="30659932"></a>Malfará BN, Benzi JRL, de Oliveira Filgueira GC, et al. ABCG2 c.421C&gt;A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. <i>Reprod Toxicol</i>. 2019;85:1-5. doi: 10.1016/j.reprotox.2019.01.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/30659932/pubmed" id="30659932" target="_blank">30659932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4041333">
<a name="4041333"></a>Martre H, Sari R, Taburet AM, Jacobs C, Singlas E. Haemodialysis does not affect the pharmacokinetics of nifedipine. <i>Br J Clin Pharmacol.</i> 1985;20(2):155-158. doi:10.1111/j.1365-2125.1985.tb05049.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/4041333/pubmed" id="4041333" target="_blank">4041333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19389575">
<a name="19389575"></a>McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. <i>J Am Coll Cardiol</i>. 2009;53(17):1573-1619. doi:10.1016/j.jacc.2009.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/19389575/pubmed" id="19389575" target="_blank">19389575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3307894">
<a name="3307894"></a>Meyrick Thomas RH, Rademaker M, Grimes SM, et al. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. <i>Br J Dermatol</i>. 1987;117(2):237-241. doi:10.1111/j.1365-2133.1987.tb04122.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/3307894/pubmed" id="3307894" target="_blank">3307894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33820495">
<a name="33820495"></a>Morimoto K, Yoshida T, Washida N, et al. Bullous pemphigoid in patients receiving peritoneal dialysis: a case series and a literature survey. <i>Ren Fail</i>. 2021;43(1):651-657. doi:10.1080/0886022X.2021.1910045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/33820495/pubmed" id="33820495" target="_blank">33820495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6365350">
<a name="6365350"></a>Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. <i>Circulation</i>. 1984;69(4):740-747. doi:10.1161/01.cir.69.4.740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/6365350/pubmed" id="6365350" target="_blank">6365350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34739303">
<a name="34739303"></a>Mulrenin IR, Garcia JE, Fashe MM, et al. The impact of pregnancy on antihypertensive drug metabolism and pharmacokinetics: current status and future directions. <i>Expert Opin Drug Metab Toxicol</i>. 2021;17(11):1261-1279. doi:10.1080/17425255.2021.2002845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/34739303/pubmed" id="34739303" target="_blank">34739303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1681227">
<a name="1681227"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. <i>Clinical Practice Guidelines</i>. National Institutes of Health; 2011. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1681227/pubmed" id="1681227" target="_blank">1681227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE guideline, No. 133. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7562349">
<a name="7562349"></a>Nery EB, Edson RG, Lee KK, Pruthi VK, Watson J. Prevalence of nifedipine-induced gingival hyperplasia. <i>J Periodontol.</i> 1995;66(7):572-578. doi:10.1902/jop.1995.66.7.572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/7562349/pubmed" id="7562349" target="_blank">7562349</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nifedipine capsules [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nifedipine.2">
<a name="Nifedipine.2"></a>Nifedipine capsules, USP [prescribing information]. Indianapolis, IN: Major Pharmaceuticals; March 2022.</div>
</li>
<li>
<div class="reference">
                  Nifedipine extended release tablet [prescribing information]. Orlando, FL: Ingenus Pharmaceuticals, LLC; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2002429">
<a name="2002429"></a>Nishikawa SJ, Tada H, Hamasaki A, et al. Nifedipine-induced gingival hyperplasia: a clinical and in vitro study. <i>J Periodontol.</i> 1991;62(1):30-35. doi:10.1902/jop.1991.62.1.30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2002429/pubmed" id="2002429" target="_blank">2002429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-2492. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1483797">
<a name="1483797"></a>Oelz O, Maggiorini M, Ritter M, et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. <i>Int J Sports Med</i>. 1992;13(suppl 1):S65-S68. doi:10.1055/s-2007-1024598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1483797/pubmed" id="1483797" target="_blank">1483797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Otto.1">
<a name="Otto.1"></a>Otto CA. Altitude-associated illness in children (acute mountain sickness). In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2019:chap. 90.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17018510">
<a name="17018510"></a>Page SM, McKenna DS. Vasospasm of the nipple presenting as painful lactation. <i>Obstet Gynecol</i>. 2006;108(3, pt 2):806-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/17018510/pubmed" id="17018510" target="_blank">17018510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11464254">
<a name="11464254"></a>Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. <i>J Hum Hypertens</i>. 2001;15(7):455-461. doi:10.1038/sj.jhh.1001201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11464254/pubmed" id="11464254" target="_blank">11464254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2737237">
<a name="2737237"></a>Penny WJ, Lewis MJ. Nifedipine is excreted in human milk. <i>Eur J Clin Pharmacol.</i> 1989;36(4):427-428. doi:10.1007/BF00558309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2737237/pubmed" id="2737237" target="_blank">2737237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11682018">
<a name="11682018"></a>Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. <i>High Alt Med Biol.</i> 2001;2(3):389-403. doi:10.1089/15270290152608561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11682018/pubmed" id="11682018" target="_blank">11682018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15351192">
<a name="15351192"></a>Poole-Wilson PA, Lubsen J, Kirwan BA, et al; Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. <i>Lancet.</i> 2004;364(9437):849-857. doi:10.1016/S0140-6736(04)16980-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15351192/pubmed" id="15351192" target="_blank">15351192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Procardia.1">
<a name="Procardia.1"></a>Procardia (nifedipine) [prescribing information]. New York, NY: Pfizer; July 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Procardia.2">
<a name="Procardia.2"></a>Procardia XL (nifedipine) [prescribing information]. New York, NY: Pfizer; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2467711">
<a name="2467711"></a>Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. <i>BMJ</i>. 1989;298(6673):561-564. doi:10.1136/bmj.298.6673.561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2467711/pubmed" id="2467711" target="_blank">2467711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10789602">
<a name="10789602"></a>Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. <i>Arch Intern Med.</i> 2000;160(8):1101-1108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/10789602/pubmed" id="10789602" target="_blank">10789602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1603139">
<a name="1603139"></a>Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. <i>N Engl J Med</i>. 1992;327(2):76-81. doi:10.1056/NEJM199207093270203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1603139/pubmed" id="1603139" target="_blank">1603139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23280223">
<a name="23280223"></a>Roos C, Spaanderman ME, Schuit E, et al; APOSTEL-II Study Group. Effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a randomized controlled trial. <i>JAMA.</i> 2013;309(1):41-47. doi:10.1001/jama.2012.153817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23280223/pubmed" id="23280223" target="_blank">23280223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2589350">
<a name="2589350"></a>Rosen WJ, Johnson CE. Evaluation of Five Procedures for Measuring Nonstandard Doses of Nifedipine Liquid. <i>Am J Hosp Pharm</i>. 1989;46(11):2313-2317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2589350/pubmed" id="2589350" target="_blank">2589350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1832534">
<a name="1832534"></a>Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. <i>Arch Dermatol</i>. 1991;127(9):1333-1338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1832534/pubmed" id="1832534" target="_blank">1832534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8613643">
<a name="8613643"></a>Seggev JS, Lagstein Z. Photosensitivity skin reactions to calcium channel blockers. <i>J Allergy Clin Immunol</i>. 1996;97(3):852-855. doi:10.1016/s0091-6749(96)80164-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8613643/pubmed" id="8613643" target="_blank">8613643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8699502">
<a name="8699502"></a>Silverstein LH, Koch JP, Lefkove MD, Garnick JJ, Singh B, Steflik DE. Nifedipine-induced gingival enlargement around dental implants: a clinical report. <i>J Oral Implantol.</i> 1995;21(2):116-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8699502/pubmed" id="8699502" target="_blank">8699502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simhan.1">
<a name="Simhan.1"></a>Simhan HN, Caritis S. Inhibition of acute preterm labor. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22577545">
<a name="22577545"></a>Singh D, Akingbola O, Yosypiv I, El-Dahr S. Emergency management of hypertension in children. <i>Int J Nephrol.</i> 2012;2012:420247. doi:10.1155/2012/420247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22577545/pubmed" id="22577545" target="_blank">22577545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19337538">
<a name="19337538"></a>Snider ME, Nuzum DS, Veverka A. Long-acting nifedipine in the management of the hypertensive patient. <i>Vasc Health Risk Manag</i>. 2008;4(6):1249-1257. doi:10.2147/vhrm.s3661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/19337538/pubmed" id="19337538" target="_blank">19337538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6625800">
<a name="6625800"></a>Spital A, Scandling JD. Nifedipine in continuous ambulatory peritoneal dialysis. <i>Arch Intern Med.</i> 1983;143(10):2025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/6625800/pubmed" id="6625800" target="_blank">6625800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8135450">
<a name="8135450"></a>Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. <i>Ann Intern Med.</i> 1994;120(8):663-664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8135450/pubmed" id="8135450" target="_blank">8135450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2523214">
<a name="2523214"></a>Stern R, Khalsa JH. Cutaneous adverse reactions associated with calcium channel blockers. <i>Arch Intern Med</i>. 1989;149(4):829-832.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2523214/pubmed" id="2523214" target="_blank">2523214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27926552">
<a name="27926552"></a>Stewart DB Sr, Gaertner W, Glasgow S, Migaly J, Feingold D, Steele SR. Clinical practice guideline for the management of anal fissures. <i>Dis Colon Rectum</i>. 2017;60(1):7-14. doi:10.1097/DCR.0000000000000735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/27926552/pubmed" id="27926552" target="_blank">27926552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15546967">
<a name="15546967"></a>Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. <i>Rheumatology (Oxford)</i>. 2005;44(2):145-150. doi:10.1093/rheumatology/keh390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15546967/pubmed" id="15546967" target="_blank">15546967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3726585">
<a name="3726585"></a>Thomas E, Witt P, Willis M, Morse J. Nifedipine therapy for diffuse esophageal spasm. <i>South Med J</i>. 1986;79(7):847-849. doi:10.1097/00007611-198607000-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/3726585/pubmed" id="3726585" target="_blank">3726585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19584474">
<a name="19584474"></a>Tripathy S, Mishra M. Nifedipine-induced acute generalized exanthematous pustulosis in a case of acute glomerulonephritis. <i>Indian J Dermatol Venereol Leprol</i>. 2009;75(4):408-410. doi:10.4103/0378-6323.53150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/19584474/pubmed" id="19584474" target="_blank">19584474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36104450">
<a name="36104450"></a>van de Vusse D, Mian P, Schoenmakers S, et al. Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. <i>Eur J Clin Pharmacol.</i> 2022;78(11):1763-1776. doi:10.1007/s00228-022-03382-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/36104450/pubmed" id="36104450" target="_blank">36104450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15777455">
<a name="15777455"></a>van Veen AJ, Pelinck MJ, van Pampus MG, Erwich JJ. Severe hypotension and fetal death due to tocolysis with nifedipine. <i>BJOG</i>. 2005;112(4):509-510. doi:10.1111/j.1471-0528.2004.00480.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15777455/pubmed" id="15777455" target="_blank">15777455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varon.1">
<a name="Varon.1"></a>Varon J, Elliott WJ. Management of severe asymptomatic hypertension (hypertensive urgencies) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28333939">
<a name="28333939"></a>Verspyck E, de Vienne C, Muszynski C, et al. Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial. <i>PLoS One</i>. 2017;12(3):e0173717. doi:10.1371/journal.pone.0173717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/28333939/pubmed" id="28333939" target="_blank">28333939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3827433">
<a name="3827433"></a>Wachter RM. Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension. <i>Arch Intern Med</i>. 1987;147(3):556-558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/3827433/pubmed" id="3827433" target="_blank">3827433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34618700">
<a name="34618700"></a>Wald A, Bharucha AE, Limketkai B, et al. ACG clinical guidelines: management of benign anorectal disorders. <i>Am J Gastroenterol</i>. 2021;116(10):1987-2008. doi:10.14309/ajg.0000000000001507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/34618700/pubmed" id="34618700" target="_blank">34618700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi:10.1111/jch.12237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9249636">
<a name="9249636"></a>Westbrook P, Bednarczyk EM, Carlson M, Sheehan H, Bissada NF. Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. <i>J Periodontol.</i> 1997;68(7):645-650. doi:10.1902/jop.1997.68.7.645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/9249636/pubmed" id="9249636" target="_blank">9249636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12324557">
<a name="12324557"></a>Wigley FM. Clinical practice. Raynaud's phenomenon. <i>N Engl J Med.</i> 2002;347(13):1001-1008. doi:10.1056/NEJMcp013013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/12324557/pubmed" id="12324557" target="_blank">12324557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wigley.1">
<a name="Wigley.1"></a>Wigley FM. Treatment of Raynaud phenomenon: Initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 31, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22270434">
<a name="22270434"></a>Wu M, Chason R, Wong M. Raynaud's phenomenon of the nipple. <i>Obstet Gynecol</i>. 2012;119(2, pt 2):447-449. doi:10.1097/AOG.0b013e31822c9a73<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22270434/pubmed" id="22270434" target="_blank">22270434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19552357">
<a name="19552357"></a>Wynn RL. Calcium channel blockers and gingival hyperplasia--an update. <i>Gen Dent.</i> 2009;57(2):105-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/19552357/pubmed" id="19552357" target="_blank">19552357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21083640">
<a name="21083640"></a>Ye Z, Yang H, Li H, et al. A multicentre, prospective, randomized trial: comparative efficacy of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with renal colic. <i>BJU Int</i>. 2011;108(2):276-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/21083640/pubmed" id="21083640" target="_blank">21083640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15054645">
<a name="15054645"></a>Yiu V, Orrbine E, Rosychuk RJ, et al. The safety and use of short-acting nifedipine in hospitalized hypertensive children. <i>Pediatr Nephrol.</i> 2004;19(6):644-650. doi:10.1007/s00467-004-1444-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15054645/pubmed" id="15054645" target="_blank">15054645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1831774">
<a name="1831774"></a>Zenarola P, Gatti S, Lomuto M. Photodermatitis due to nifedipine: report of 2 cases. <i>Dermatologica</i>. 1991;182(3):196-198. doi:10.1159/000247783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1831774/pubmed" id="1831774" target="_blank">1831774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19493392">
<a name="19493392"></a>Zhang MY, Ding ST, Lü JJ, et al. Comparison of tamsulosin with extracorporeal shock wave lithotripsy in treating distal ureteral stones. <i>Chin Med J (Engl)</i>. 2009;122(7):798-801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/19493392/pubmed" id="19493392" target="_blank">19493392</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9700 Version 639.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
